Bill & Melinda Gates Foundation grants USD 128m to Pfizer for RSV and GBS vaccines

Pfizer has received funding to bring vaccines to lower-income countries, targeting infections that are potentially deadly for infants.

Ted S. Warren/AP/Ritzau Scanpix

The Bill & Melinda Gates Foundation is sending USD 128m to Pfizer for the purpose of supporting the development of vaccines against the respiratory syncytial virus, RSV, and group B streptococcus (GBS), a press release announces.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs